13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Epilepsy and Seizure Disorders
Epilepsy and seizure disorders represent a group of neurological conditions that result in unpredictable and often disabling seizures, which can have profound effects on quality of life. Diagnosis involves a detailed clinical assessment and advanced diagnostic tools such as EEG monitoring and functional imaging to localize seizure foci in the brain. Despite the availability of a variety of antiepileptic medications, many patients continue to experience uncontrolled seizures, highlighting the need for more targeted treatments. Emerging therapies in the field include responsive neurostimulation, deep brain stimulation, and novel pharmacological agents that aim to modify the underlying pathophysiology. Additionally, exploring the role of inflammation, genetic predisposition, and neuroplasticity in epilepsy is providing new insights into how to better manage and potentially cure these disorders.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States